Literature DB >> 4005805

The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients.

R J Kurman, P F Kaminski, H J Norris.   

Abstract

Endometrial curettings from 170 patients with all grades of endometrial hyperplasia, who did not undergo a hysterectomy for at least 1 year were evaluated in order to correlate the histopathologic features with behavior. Follow-up ranged from 1 to 26.7 years (mean, 13.4 years). Cytologic and architectural alterations were analyzed separately in order to assess their respective roles in predicting the likelihood of progression to carcinoma. Classification of proliferative lesions based solely on the presence of cytologic atypia revealed that atypia was a discriminant factor. Proliferations lacking cytologic atypia were designated hyperplasia and those displaying atypia were designated atypical hyperplasia. Only 2 (1.6%) of 122 patients with hyperplasia progressed to carcinoma compared with 11 (23%) of women with atypical hyperplasia (P = 0.001). Subclassification of the two forms of hyperplasia (those with cytologic atypia and those without) was performed using the degree of architectural abnormalities. Hyperplasia and atypical hyperplasia displaying marked glandular complexity and crowding producing a back-to-back appearance were designated complex hyperplasia (CH) and complex atypical hyperplasia (CAH), respectively. Hyperplasia and atypical hyperplasia with lesser degrees of glandular complexity and crowding were designated simple hyperplasia (SH) and simple atypical hyperplasia (SAH), respectively. Progression to carcinoma occurred in 1 (1%) of 93 patients with SH, in 1 (3%) of 29 patients with CH, in 1 (8%) of the patients with SAH, and in 10 (29%) of the patients with CAH. The differences between the four subgroups suggest a trend but are not statistically significant. The findings in this study provide a rationale for classifying noninvasive endometrial proliferations primarily on the basis of cytologic atypia since this is the most useful criterion in predicting the likelihood of progression to carcinoma. In addition, the presence of concommitant architectural alterations appears to identify a particularly high-risk subgroup.

Entities:  

Mesh:

Year:  1985        PMID: 4005805     DOI: 10.1002/1097-0142(19850715)56:2<403::aid-cncr2820560233>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  167 in total

Review 1.  The menopause and its treatment in perspective.

Authors:  F Al-Azzawi
Journal:  Postgrad Med J       Date:  2001-05       Impact factor: 2.401

2.  Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.

Authors:  Kristen Upson; Kimberly H Allison; Susan D Reed; Carolyn D Jordan; Katherine M Newton; Elizabeth M Swisher; Jennifer A Doherty; Rochelle L Garcia
Journal:  Am J Obstet Gynecol       Date:  2012-05-16       Impact factor: 8.661

3.  Endometrial cancer.

Authors:  Kimberly K Leslie; Kristina W Thiel; Michael J Goodheart; Koen De Geest; Yichen Jia; Shujie Yang
Journal:  Obstet Gynecol Clin North Am       Date:  2012-06       Impact factor: 2.844

4.  Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.

Authors:  Henry D Reyes; Matthew J Carlson; Eric J Devor; Yuping Zhang; Kristina W Thiel; Megan I Samuelson; Megan McDonald; Shujie Yang; Jean-Marie Stephan; Erica C Savage; Donghai Dai; Michael J Goodheart; Kimberly K Leslie
Journal:  Gynecol Oncol       Date:  2015-10-30       Impact factor: 5.482

Review 5.  Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases.

Authors:  Mi-La Kim; Seok Ju Seong
Journal:  Obstet Gynecol Sci       Date:  2013-03-12

6.  Uterine epithelial cell proliferation and endometrial hyperplasia: evidence from a mouse model.

Authors:  Yang Gao; Shu Li; Qinglei Li
Journal:  Mol Hum Reprod       Date:  2014-04-25       Impact factor: 4.025

7.  Pathology of endometrium treated with tamoxifen.

Authors:  S M Ismail
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

Review 8.  Management of endometrial precancers.

Authors:  Cornelia L Trimble; Michael Method; Mario Leitao; Karen Lu; Olga Ioffe; Moss Hampton; Robert Higgins; Richard Zaino; George L Mutter
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

9.  Endometrial hyperplasia: a clinicopathological study in a tertiary care hospital.

Authors:  Gargi Raychaudhuri; Anjali Bandyopadhyay; Dipnarayan Sarkar; Sarbeswar Mandal; Sajeeb Mondal; Pradip Kumar Mitra
Journal:  J Obstet Gynaecol India       Date:  2013-06-27

10.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.